drugset
drugset / Trial / NCT04971395

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

NCT04971395 ↗

Phase 1 Completed 25 enrolled Xentria, Inc.
RandomizedSequentialDouble-blindOther

Summary

This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.

Timeline

Start
2021-06-25
Primary completion
2022-03-18
Completion
2022-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject XTMAB-16 Unknown 2 mg/kg Intravenous
Subject XTMAB-16 Unknown 4 mg/kg Intravenous

Indications

No indication recorded.